Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (51-60 of 234) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Determining the best dose for the individual patientRon H J Mathijssen, Walter J Loos, Jaap Verweij
Investigational New Drugs|August 2, 2003
Clinical trial design for target specific anticancer agentsRonald Hoekstra, Jaap Verweij, Ferry A L M Eskens
European Journal of Cancer (Oxford, England : 1990)|August 10, 2010
Dose-escalation models for combination phase I trials in oncologyPaul Hamberg, Mark J Ratain, Emmanuel Lesaffre, et al.
Molecular Oncology|March 6, 2012
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designJaap Verweij, Maja de Jonge, Ferry Eskens, et al.
Anti-Cancer Drugs|December 13, 2006
Alternative drug formulations of docetaxel: a reviewFrederike K Engels, Ron A A Mathot, Jaap Verweij
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Interaction of Cisplatin with the human organic cation transporter 2Kelly K Filipski, Walter J Loos, Jaap Verweij, et al.
Cancer Biology & Therapy|December 21, 2007
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinibErin R Gardner, Alex Sparreboom, Jaap Verweij, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 9, 2003
Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matricesOtto Soepenberg, Peter de Bruijn, Jaap Verweij, et al.
Clinical Pharmacokinetics|July 8, 2003
Pharmacological effects of formulation vehicles : implications for cancer chemotherapyAlbert J ten Tije, Jaap Verweij, Walter J Loos, et al.
Cancers|August 23, 2020
Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in EuropeCarin A Uyl-de Groot, Renaud Heine, Marieke Krol, et al.
Pageof 24

Showing results (51-60 of 234) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Determining the best dose for the individual patientRon H J Mathijssen, Walter J Loos, Jaap Verweij
Investigational New Drugs|August 2, 2003
Clinical trial design for target specific anticancer agentsRonald Hoekstra, Jaap Verweij, Ferry A L M Eskens
European Journal of Cancer (Oxford, England : 1990)|August 10, 2010
Dose-escalation models for combination phase I trials in oncologyPaul Hamberg, Mark J Ratain, Emmanuel Lesaffre, et al.
Molecular Oncology|March 6, 2012
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designJaap Verweij, Maja de Jonge, Ferry Eskens, et al.
Anti-Cancer Drugs|December 13, 2006
Alternative drug formulations of docetaxel: a reviewFrederike K Engels, Ron A A Mathot, Jaap Verweij
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Interaction of Cisplatin with the human organic cation transporter 2Kelly K Filipski, Walter J Loos, Jaap Verweij, et al.
Cancer Biology & Therapy|December 21, 2007
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinibErin R Gardner, Alex Sparreboom, Jaap Verweij, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 9, 2003
Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matricesOtto Soepenberg, Peter de Bruijn, Jaap Verweij, et al.
Clinical Pharmacokinetics|July 8, 2003
Pharmacological effects of formulation vehicles : implications for cancer chemotherapyAlbert J ten Tije, Jaap Verweij, Walter J Loos, et al.
Cancers|August 23, 2020
Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in EuropeCarin A Uyl-de Groot, Renaud Heine, Marieke Krol, et al.
Pageof 24